Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | COPS5 | Q92905 | 7/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487227 | 0.83 | COPS5 (0.44) | ALDH1A1KDM4EPKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL11035827 | 0.81 | ALDH1A1 (0.35) | ALDH1A1KDM4EPKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL10428685 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EPKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL10428686 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EPKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL4253876 | 0.76 | COPS5 (0.40) | ALDH1A1KDM4EPKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL13451813 | 0.76 | ALDH1A1 (0.37) | ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL13609511 | 0.74 | ALDH1A1 (0.53) | ALDH1A1KDM4EPKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL3046694 | 0.73 | KDM4E (0.59) | ALDH1A1KDM4EPKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL10897593 | 0.73 | KDM4E (0.39) | ALDH1A1KDM4EPKMSMN1; SMN2L3MBTL1 | |
| SCHEMBL965928 | 0.73 | KDM4E (0.39) | ALDH1A1KDM4EPKMSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1921074-A1 | THIAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | GK, GCKR, AK2 | ALDH1A1 1817/4885KDM4E 2709/4885PKM 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.